Source: Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017

Member's Comments

No comment yet.

Related content which might interest you: Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity? Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 830-836 Year: 2010 Early decrease of forced vital capacity is a good prediction tool for prognosis in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Exercise capacity in idiopathic pulmonary fibrosis and COPD Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Post-bronchodilator FVC determines pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary disease Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions? Year: 2011 The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Determinants of exercise limitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 107s Year: 2005 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015